newsfilter
← Latest News
GlobeNewswire·

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

  • CDT Equity Inc. announced that Sarborg Limited filed a new Substance of Matter patent covering two established cystic fibrosis compounds.
  • The patent was developed using Sarborg's proprietary Signature Agent and Multi-Agent platform, supported by its 1,600 Disease Database and 1,700 Rare Disease Database.
  • Sarborg achieved the patent filing in less than three weeks, enabling rapid identification of new therapeutic opportunities.
  • As a 20% shareholder, CDT views the development as validation of Sarborg's ability to generate high-value intellectual property quickly.
  • CDT is collaborating with Sarborg to evaluate its asset portfolio for potential combination therapies involving CDT assets and Sarborg's patented compounds.
  • CDT intends to leverage this partnership to expand its intellectual property position and unlock additional commercial opportunities.
  • The press release includes forward-looking statements regarding future operations, product approvals, and strategic plans subject to various risks.